Andrew T. Kaplan bought stock once, on Apr 20, 2026
Director and 10% owner at Kailera Therapeutics, Inc., and 1 other company
SEC CIK 0001752059 · Filings on SEC.gov ↗
Andrew T. Kaplan's record
3 months after each buy, from the first price a copier could get.
1 buy has 3 months of prices so far. A record shows here at 3.
Companies
Every filing
2 filings since Dec 2023, newest first
About Andrew T. Kaplan
Andrew T. Kaplan is a Partner at Bain Capital in the North America Private Equity team, focusing on healthcare investments.( He serves on the Board of Directors of Kailera Therapeutics, Inc. (KLRA) as a Director, where he led the $600 million Series B funding round in October 2025.( Kaplan holds an MBA from Harvard Business School as a Baker Scholar and a B.S. in economics, magna cum laude, from the Wharton School.(
Earlier in his career, Kaplan worked as an investment banker at Goldman Sachs and co-founded EngagedHealth, a post-hospitalization service aimed at improving outcomes for chronically ill patients.( He also serves on the boards of Beeline Medicines, QuVa Pharma, Surgery Partners, U.S. Renal Care, PCI Pharma Services, and as a Governing Trustee of the Dana-Farber Cancer Institute.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.